ASSESSMENT OF THE RESPONSE OF PATIENTS WITH CROHN'S DISEASE TO BIOLOGICAL THERAPY USING NEW NON-INVASIVE MARKERS: lactoferrin and calprotectin

Nogueira, Islaine Martins; Miszputen, Sender Jankiel; Ambrogini, Orlando; Neto, Ricardo Artigiani; Carvente, Cláudia Teresa; Zanon, Maria Ivani

doi:10.1590/s0004-28032013000200022

Cited by 9 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The researchers showed that before the administration of biological treatment faecal markers can be an accurate measure of endoscopic and histological remission, but during the course of the disease they do not correlate as precisely with the endoscopic activity of the disease. The authors concluded that the biomarkers are useful in the long-term evaluation of biological treatment [21]. Our results are different to these observations, but consistent with data from Sipponen et al In our study, during the course of biological treatment the concentration of both calprotectin and lactoferrin decreased, which still correlated with the endoscopic and clinical activity of the disease.…”

Section: Discussionsupporting

confidence: 87%

Diagnostic importance of faecal markers in long-term monitoring of anti-TNF- therapy in primary responders with Crohn’s disease

Łykowska‐Szuber

Klimczak

Eder

et al. 2016

View full text Add to dashboard Cite

IntroductionMonitoring the response to biological treatment in Crohn’s disease (CD) is a very important element of the therapeutic optimisation.AimTo evaluate the usefulness of measuring calprotectin, lactoferrin, and myeloperoxidase in stool as markers of long-term clinical and endoscopic response to anti-tumour necrosis factor α (anti-TNF) treatment in CD.Material and methodsThe studied group consisted of 35 CD patients treated with anti-TNF-α antibodies. Clinical activity was evaluated using Crohn’s Disease Activity Index (CDAI), and the exacerbation of endoscopic changes was evaluated using a Simple Endoscopic Score for Crohn’s Disease (SES-CD). The concentration of calprotectin, lactoferrin, and myeloperoxidase was measured using the ELISA method. All measurements were performed three times – before, after 3 months, and after a year of therapy.ResultsDuring anti-TNF treatment the concentrations of all measured faecal markers decreased significantly in relation to baseline values. We observed a significant correlation at all time-points: before the therapy, after 3 months, and 12 months after starting the therapy, between the concentration of calprotectin and SES-CD, calprotectin and CDAI, as well as between lactoferrin and SES-CD, and lactoferrin and CDAI. Myeloperoxidase correlated with both SES-CD and CDAI only after 1 year of treatment.ConclusionsFaecal calprotectin and lactoferrin are valuable markers of clinical and endoscopic activity of CD in patients treated with anti-TNF antibodies. They are useful in monitoring the response to treatment. The usefulness of myeloperoxidase in this respect remains controversial.

show abstract

Section: Discussionsupporting

confidence: 87%

Diagnostic importance of faecal markers in long-term monitoring of anti-TNF- therapy in primary responders with Crohn’s disease

Łykowska‐Szuber

Klimczak

Eder

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Recently, Kopylov et al (11) published a review article concerning the clinical utility of fecal biomarkers, including calprotectin, for the diagnosis and management of IBD. There is scarce information about the use of this test in Brazilian patients (18,32) . The aims of the present study were to prospectively investigate, in Brazilian adults with gastrointestinal complaints, the value of FC as a biomarker for the differential diagnosis between functional and organic disorders and to correlate the concentrations with the activity of IBD.…”

Section: Introductionmentioning

confidence: 99%

FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms

Kotze

Nisihara

Marion

et al. 2015

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Background -Determination of fecal calprotectin can provide an important guidance for the physician, also in primary care, in the differential diagnosis of gastrointestinal disorders, meanly between inflammatory bowel diseases and irritable bowel syndrome. Objectives -The aims of the present study were to prospectively investigate, in Brazilian adults with gastrointestinal complaints, the value of fecal calprotectin as a biomarker for the differential diagnosis between functional and organic disorders and to correlate the concentrations with the activity of inflammatory bowel diseases. Methods -The study included consecutive patients who had gastrointestinal complaints in which the measurement levels of fecal calprotectin were recommended. Fecal calprotectin was measured using a Bühlmann (Basel, Switzerland) ELISA kit.

show abstract

“…In another study of 115 CD patients, FC less than 300 μg/g was associated with a reduced risk of disease relapse . However, not all the data are in line with these observations, as reported in a prospective study measuring FC levels in patients undergoing infliximab induction . In these patients, FC measurement at 14 weeks could not predict CD clinical relapse at 1 year, suggesting a limit in the reliability of the marker over a long time.…”

Section: Discussionmentioning

confidence: 86%

“…Repeated measurement of FC indicates that a drop of pretreatment stool concentration is effective in predicting response to anti‐tumor necrosis factor‐α antibodies. Again, differing reduction values versus baseline were used for predicting favorable responses (Table ) …”

Section: Resultsmentioning

confidence: 99%

“…Again, differing reduction values versus baseline were used for predicting favorable responses (Table 4). [36][37][38][39][40][41][42][43][44] Conversely, minor reductions of FC (< 70%) after anti-tumor necrosis factor-α antibodies induction predict non-response. 42 14 50 μg/g 59 71 --P = 0.008 Sipponen 2012 29 14 100 μg/g 36 89 --P = 0.008 Höög 2014 26 30 ---Lewis score Inclusion r = 0.54 Inclusion P = 0.003 Höög 2014 26 30 ---Lewis score Follow-up r = 0.83 Follow-up P < 0.001 Egea-Valenzuela 2015 25 68 50 μg/g 96 23 Lewis score r 2 = 0.1 -Egea-Valenzuela 2015 25 34 100 μg/g 75 67…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Is fecal calprotectin an accurate marker in the management of Crohn's disease?

Vernia

Ruscio

Stefanelli

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

Although lacking validated cutoff values, fecal calprotectin (FC), besides C‐reactive protein, is considered the standard test for assessing disease activity in Crohn's disease (CD). The aim of the present review is to provide a general overview of the literature addressing the role of FC in the clinical and endoscopic assessment of disease activity in CD, seeking correlations with capsule endoscopy, response to therapy, prediction of relapse, and postoperative recurrence. A systematic search of the literature up to September 2019 was performed using Medline, Embase, and the Cochrane Library. Only papers written in English concerning FC in adult patients affected by CD were included. Pediatric studies, in vitro studies, animal studies, studies on blood/serum samples, and studies analyzing FC in ulcerative colitis or in both CD and ulcerative colitis were excluded. Out of 713 citations, 65 eligible studies were identified. FC showed high accuracy in the assessment of intestinal inflammation and response to therapy, in particular in colonic disease, thus proving a good surrogate marker for these aims. FC is useful in identifying patients at high risk for endoscopic relapse or postoperative recurrence, for optimizing or downstage therapy. Unfortunately, FC performs less well in small bowel CD. FC is an effective fecal marker in the management of CD patients, optimizing the use of endoscopic procedures. Owing to its diagnostic accuracy, FC may represent a cornerstone of the “treat‐to‐target” management strategy of CD patients.

show abstract

ASSESSMENT OF THE RESPONSE OF PATIENTS WITH CROHN'S DISEASE TO BIOLOGICAL THERAPY USING NEW NON-INVASIVE MARKERS: lactoferrin and calprotectin

Abstract: Calprotectin and lactoferrin are not useful for monitoring inflammatory activity in Crohn's disease patients who are subjected to biological therapy.

Cited by 9 publications

References 34 publications

Diagnostic importance of faecal markers in long-term monitoring of anti-TNF- therapy in primary responders with Crohn’s disease

Diagnostic importance of faecal markers in long-term monitoring of anti-TNF- therapy in primary responders with Crohn’s disease

FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms

Is fecal calprotectin an accurate marker in the management of Crohn's disease?

Contact Info

Product

Resources

About